Apr 25, 2025   SOURCE: PR NewsWire

WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

SUNNYVALE, Calif., April 25, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on April 25, 2025 (the "Meeting"). A total of 59,214,893 common shares, representing approximately 40.88% of the Company's issued and outstanding shares were represented at the meeting.

The shareholders approved the setting of the number of directors of Willow at 5 directors, and the following nominees were elected as directors of Willow for the ensuing year with the specific voting results being as follows:

                         
            Votes For            Votes Withheld



     Director         
            #             %  
           #             %



     Dr. Chris Savile  46,902,346        88.3 %   6,234,676        11.7 %



     Dr. Jim Lalonde   46,965,380        88.4 %   6,171,642        11.6 %



     Donald Archibald  44,900,287        84.5 %   8,236,735        15.5 %



     Raffi Asadorian   46,963,057        88.4 %   6,173,965        11.6 %



     Al Foreman        46,900,723        88.3 %   6,236,299        11.7 %

In addition, shareholders approved the below matters. The resolutions approving the below matters may be viewed in full in the Company's management information circular dated March 26, 2025 (the "Information Circular").

                                                                                                          Votes For



              Director                                                                      
              #             %



              Appointment of KPMG LLP as the Company's auditor for the ensuring year          51,882,364         87.6 %



              The proposed sale of the shares of Epimeron USA, Inc., the Corporation's        46,996,397         88.4 %
    wholly-owned subsidiary, as more particularly described in the Information Circular



              To authorize the Corporation's board of directors, at its sole discretion, to   48,853,362         82.5 %
    amend the Articles of the Corporation to change its name from "Willow
    Biosciences Inc." to "2482118 Alberta Ltd.", or such other name as may be
    approved by the Board, as more particularly described in the Information Circular.

For complete voting results on all matters approved at the Meeting, please see the Company's Report of Voting Results dated April 25, 2025, available on SEDAR+ at www.sedarplus.ca.

About Willow Biosciences Inc.

Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrown(TM) biotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.

For more information, visit www.willowbio.com or contact:

Travis Doupe
Chief Financial Officer
E: info@willowbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/willow-biosciences-announces-annual-general-and-special-meeting-voting-results-302438831.html

SOURCE Willow Biosciences Inc.